Form 4: Beam Therapeutics President Giuseppe Ciaramella Receives 35,000 Restricted Stock Units

Giuseppe Ciaramella, President of Beam Therapeutics, reports the acquisition of 35,000 restricted stock units (RSUs) on March 31, 2024.

Summary

• Giuseppe Ciaramella, President of Beam Therapeutics Inc., filed a Form 4 on April 2, 2024, reporting a transaction that occurred on March 31, 2024.
• Ciaramella acquired 35,000 shares of common stock in the form of restricted stock units (RSUs).
• These RSUs were granted under the Beam Therapeutics Inc. 2019 Equity Incentive Plan.
• Each RSU represents the right to receive one share of BEAM's common stock.
• The RSUs vest in four equal installments on the first four anniversaries of the grant date, contingent upon Ciaramella's continued service with Beam Therapeutics.
• Following the reported transaction, Ciaramella beneficially owns 174,150 shares of Beam Therapeutics common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of RSUs is a standard practice and indicates confidence in the executive and the company's future.

Positives

• The grant of RSUs aligns the executive's interests with those of the shareholders, incentivizing continued service and performance.

Future Outlook

The vesting schedule of the RSUs suggests an expectation of continued service from the executive over the next four years.

Industry Context

Equity compensation is a common practice in the biotechnology industry to attract and retain key talent. RSU grants are a typical component of executive compensation packages.

Comparison to Industry Standards

• RSU grants are a standard form of compensation for executives in publicly traded biotech companies.
• The size of the grant would be benchmarked against similar roles and company size within the industry.
• Companies like CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics also utilize RSU grants as part of their executive compensation packages.

Stakeholder Impact

• The RSU grant aligns management's interests with shareholders, potentially leading to increased shareholder value.

Key Dates